In pts w/o RF, liver bx prev suggestd if lifetime cumulative MTX dose was 1-1.5g, then 3.5-4g. All pts in centre offered Fibroscan liver stifness associations: - age, BMI - not cumulative MTX dose maybe survival bias, but what we're doing now is fine! #ACR21 ABST0786 @RheumNow https://t.co/I6IhS3jhmC

Does concomitant SJS affect tx effectiveness in RA? Abst#0839 suggest yes! ➡️RA+SjS have an inferior response to TNFi than RA patients w/o SjS BUT, RA/SJS pts w/ longer RA dz duration & ↑ DAS28 + HAQ-scores. What's your clinical experience with this? #ACR21 @Rheumnow https://t.co/TIc3raMOSJ

Abst#0572: In US veterans w/ RA followed for 17 yrs, several cytokines+chemokines ⭐️Associated w/ ↑ risk of incident MACE independent of typical CVD RF & RA activity & ⭐️Predicted MACE even if in LDA/remission WOW! We need to do better @ CVD risk strat! #ACRBest @RheumNow https://t.co/J74rRa9EQE

⭐️2 polyunsaturated fatty acid lipid mediator profiles are significantly associated w/ incident inflammatory arthritis in ACPA+ pts ➡️If validated, this would be of great utility in determining which pts w/ pre-clinical sero+ should be treated! Abst#0590 at #ACR21 @RheumNow https://t.co/KGEwiY6G2Q

Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients Rubbert-Roth and colleagues found: - RA patients developed anti-S1 antibodies slower and lower compared to controls - Reduced titers among Abatacept & JAKi users #ACR21 @RheumNow https://t.co/sXW8d53O8m

Post-Hoc of ASCORE trial: ➡️RA w/ mod-high dz on SQ ABAtacept as 1st line tx w/ better retention vs receiving it as 2nd line tx independent of b/l duration of dz ➤Do you use ABA as 1st line treatment for RA, when/if insurance allows? Comment below! Abst#0816 #ACR21 @RheumNow https://t.co/TRJga4OfiW

NORD-STAR Trial: outcomes in tx-naïve, early RA pts after 48w of csDMARDs+GC vs bDMARD (ABAtacept, CerToliZumab, or ToCiluZumab)+MTX ➡️ Superior CDAI remission rates w/ ABA+MTX & CZP+MTX but not TCZ+MTX vs csDMARD+GC ➡️Imaging progression low in all Abst#0825 #ACR21 @RheumNow https://t.co/QaFIF4WNEG

⭐️RA pts w/ high adipokines (fat-secreted proteins) have lower rates of LDA + remission independent of b/l dz activity & BMI ⭐️↑ adipokines esp adiponectin, then more likely to need b/tsDMARD ➡️Adipokines may be prognostic biomarkers 4 refractory dz. Abst#0789 #ACR21 @RheumNow https://t.co/AFT22TzTFp

Abst 0981 Interesting study by Singer & colleagues examining economical and clinical burden of herpes zoster in patients with RA - RA + HZ --> higher odds health resource utilization - RA + HZ --> higher costs $$$ #ACR21 @RheumNow https://t.co/6Oc7ymbKHQ

TOFA Post hoc analysis on 2000pts: ⬆️ Paraoxonase PON1 activity associated w/ ⬇ risk of malignancies (not NMSC) in RA pts treated w/ TOFA, Adj on RA duration, age, and smoking. A promising biomarker! #Abst980 @RheumNow #ACR21 https://t.co/fOILnAyDN9

#Abs0588 Effectiveness of TNFi vs non-TNFis in obese patients with #rheumatic disease @MilenaGianfran: 👉🏼>16000pts @ACRheum RISE 👉🏼Abatacept➡️larger decreases in CDAI in obese pts 👉🏼Tocilizumab➡️larger decreases in CDAI in non-obese pts @RheumNow #ACR21 https://t.co/bL5xnG1iNh

• Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Pa…

B cell repertoire: the new 🔮? An algorithm associating baseline CDAI to BCR sequencing outcomes w/ ✨Isotypes frequency ✨Somatic Hypermutations predicts MTX 12mo response w/ 78% sens & spe #Abstr982 #ACR21 @RheumNow https://t.co/SZaip6xUaO https://t.co/fbWq34gtzc

• B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Mo…

Had the pleasure of interviewing @MyasoedovaElena from Mayo Clinic on Cognitive Function and RA #ACR21 @RheumNow https://t.co/SuXeMhUvk0

• Cognitive Function and Rheumatoid Arthritis: Dr. Akhil Sood Interviews Dr. Elen…